SAN DIEGO, Oct. 6, 2021 /PRNewswire/ -- Cue Health
Inc. (Nasdaq: HLTH), a mission-driven healthcare technology
company, today introduced its new collaboration with Google Cloud
to address the nation's critical need for real-time respiratory
viral variant sequencing and tracking. The new capabilities will be
built into the Cue Integrated Care Platform, which features the Cue
Health Monitoring System and first-of-its-kind molecular COVID-19
test -- authorized by the FDA for at-home, over-the-counter use,
with accurate results delivered to mobile devices in approximately
20 minutes. Cue Health aims to harness the power of Google Cloud's
leading-edge artificial intelligence (AI), machine learning (ML),
analytics, and privacy and security tools to enhance and scale Cue
Health's platform to the benefit of all stakeholders in the ongoing
fight against this and future pandemics.
By integrating cloud-connected COVID-19 information with
sequencing data and AI tools, Cue Health and Google Cloud
will equip public health officials and researchers with
critical, real-time information about variant types -- including
their geographic distribution -- and predictive capabilities to
help identify and curb emerging threats. Cue Health's Google
Cloud-enabled infrastructure and integrated sequencing capabilities
are intended to be a useful tool not only in the fight against
COVID-19 but also to mitigate future outbreaks of other infectious
diseases, such as influenza and respiratory syncytial virus (RSV),
areas in which Cue Health is currently developing future test
offerings.
"At Cue, we aim to provide people with access to their health
information through a platform that is easy to use, portable,
connected, and fast," said Ayub
Khattak, CEO and co-founder of Cue Health. "Thanks to our
relationships with the Departments of Defense and Health and Human
Services, we're already making an impact in many states, where it's
been extremely gratifying to see Cue help make health information
accessible and timely. Together with Google Cloud, we can combine
immediate and connected lab-quality diagnostics with the power of
genome sequencing and AI-enabled predictive capabilities to develop
a new kind of tool for public health."
"Cue Health is pioneering critical technology that has already
had a huge impact on the fight against COVID-19," said Janet Kennedy, Vice President, North America
Regions, Google Cloud. "Through this collaboration, we're bringing
Google Cloud's expertise in data analytics, AI and ML to Cue,
helping them to reach even more communities and have an even
greater impact in helping to identify, predict and mitigate the
spread of infectious diseases."
Through its suite of innovative products and security solutions,
Google Cloud's tools are already enabling Cue Health to provide its
COVID-19 tests to communities across the nation. Cue Health's
COVID-19 test has been deployed into thousands of schools,
protecting not only students, faculty, and staff but also family
and community members.
"Families are pleased when the Cue Health test can be performed
at school and their children do not require absence for an extended
period of time while waiting for traditional laboratory test
results. It's really a win, win for everyone. We hope to expand
testing in our district in the near future because the Cue Health
Monitoring System is so easy and convenient," said Lori Schneider, Director of Nursing Services for
the Fairbanks, Alaska North Star
Borough School District.
Cue Health's COVID-19 tests are also being used daily in a
variety of other settings where a highly accurate, no-compromise
testing solution is required, from nursing homes and correctional
facilities to hospitals, community health clinics, and world-class
organizations.
About Cue Health
Cue Health (Nasdaq: HLTH) is a mission-driven healthcare technology
company that puts consumers in control of their health information
and places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without physician supervision. Outside
the United States, Cue Health has
received the CE mark in the European Union, Interim Order
authorization from Health Canada, and regulatory approval from
India's Central Drugs Standard
Control Organisation. Cue Health was founded in 2010 and is
headquartered in San Diego. For
more information, please visit www.cuehealth.com.
About The Cue Health Platform
The Cue Health Platform combines the hardware of the Cue Health
Monitoring System and the chemistry in the Cue Health test
cartridges with cloud-based analytics and security to run and
report high-quality diagnostic tests for people within minutes,
anywhere through the Cue Health Mobile Application. The Cue Health
Platform has been engineered so that it can be directly integrated
into existing workflows and on-demand services, such as
telemedicine, e-prescription services, and electronic medical
record, or EMR systems.
Forward-Looking Statements
Statements in this press release about future expectations, plans
and prospects, as well as any other statements regarding matters
that are not historical facts, may constitute "forward-looking
statements". The words, without limitation, "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "will," "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected capabilities of
the Cue Health Platform, the benefits that may be realized from Cue
Health's collaboration with Google Cloud, and the factors discussed
in the "Risk Factors" section of the prospectus dated September 23, 2021 filed by Cue Health with the
SEC. Any forward-looking statements contained in this press release
are based on the current expectations of Cue's management team and
speak only as of the date hereof, and Cue specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
This product has not been FDA cleared or approved; but has
been authorized by FDA under an Emergency Use Authorization, or
EUA. This product has been authorized only for the detection of
nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. The emergency use of this product is only authorized for
the duration of the declaration that circumstances exist justifying
the authorization of emergency use of in vitro diagnostics for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §
360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-collaborates-with-google-cloud-to-add-variant-sequencing-tracking-and-predictive-capabilities-to-its-cue-platform-301394133.html
SOURCE Cue Health Inc.